Pyrosequencing-based DNA methylation profiling of Fanconi anemia/BRCA pathway genes in laryngeal squamous cell carcinoma.

Fanconi anemia (FA) associated genes [FANCA, -B, -C, FANCD1(BRCA2), -D2, -E, -F, -G, -I, -L, -M, FANCN (PALB2), FANCJ(BRIP1) and FA-linked BRCA1] encode proteins of DNA damage response pathways mutated in FA patients. FA is characterized by congenital malformations, chromosomal instability and high cancer susceptibility. FA patients have a 500-700 times higher risk of head and neck squamous cell carcinoma (HNSCC) compared to the non-FA population. As DNA methylation comprises one of the known gene inactivation mechanisms in cancer we have investigated the methylation status of 13 FA and one FA-linked gene in order to assess the role of FA in sporadic laryngeal squamous cell carcinoma (LSCC) tumor samples. Thirteen laryngeal squamous carcinoma cell lines (UT-SCC) and 64 primary laryngeal carcinoma cases were analyzed by bisulfite pyrosequencing. DNA from buccal swabs of 10 healthy volunteers was used as a control group. Promoter regions of FANCA, BRCA1 and BRCA2 displayed recurrent alterations in the methylation levels in cancer samples as compared to buccal swabs controls. For FANCA, hypomethylation was observed in 11/13 cell lines (p<0.0003) and all 64 primary larynx samples (p<0.001) compared to buccal swabs. For BRCA1, 4/13 cell lines (p=0.04) and 3/58 primary laryngeal cases (p=0.22) showed hypomethylation. In BRCA2, all 13 cell lines (p<0.0001) 4/63 primary LSCC (p<0.01) showed hypermethylation as compared to controls. In conclusion, we show recurrent alterations of DNA methylation levels in three Fanconi anemia genes which might contribute to the pathogenesis of LSCC.

[1]  Steven S. Chang,et al.  Inactivation of the Tumor Suppressor Genes Causing the Hereditary Syndromes Predisposing to Head and Neck Cancer via Promoter Hypermethylation in Sporadic Head and Neck Cancers , 2010, ORL.

[2]  Scott M Langevin,et al.  Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation , 2009, BMC Cancer.

[3]  D. Matei,et al.  Minireview: epigenetic changes in ovarian cancer. , 2009, Endocrinology.

[4]  A. Auerbach,et al.  Fanconi anemia and its diagnosis. , 2009, Mutation research.

[5]  N. Howlett,et al.  The Fanconi anemia protein interaction network: casting a wide net. , 2009, Mutation research.

[6]  M. Guida,et al.  Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesions. , 2009, European journal of gynaecological oncology.

[7]  K. Amara,et al.  Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Michael Henke,et al.  Chromosomal changes characterize head and neck cancer with poor prognosis , 2008, Journal of Molecular Medicine.

[9]  Amlan Ghosh,et al.  Role of tobacco in the development of head and neck squamous cell carcinoma in an eastern Indian population. , 2008, Asian Pacific journal of cancer prevention : APJCP.

[10]  K. Shin‐ya,et al.  FANCJ Helicase Defective in Fanconia Anemia and Breast Cancer Unwinds G-Quadruplex DNA To Defend Genomic Stability , 2008, Molecular and Cellular Biology.

[11]  J. Vermorken,et al.  Recurrent head and neck cancer: current treatment and future prospects , 2008, Expert review of anticancer therapy.

[12]  D. DiMaio,et al.  Human papillomavirus in cervical and head-and-neck cancer , 2008, Nature Clinical Practice Oncology.

[13]  M. Schmid,et al.  Disruption of the FA/BRCA pathway in bladder cancer , 2007, Cytogenetic and Genome Research.

[14]  C. Tzao,et al.  Epigenetic Inactivation of the Chromosomal Stability Control Genes BRCA1, BRCA2, and XRCC5 in Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[15]  Jicai Zhang,et al.  Hypermethylation of Tumor Suppressor Genes BRCA1, p16 and 14-3-3s in Serum of Sporadic Breast Cancer Patients , 2007, Oncology Research and Treatment.

[16]  M. Hermsen,et al.  [Tumour recurrence in squamous head and neck cancer]. , 2007, Acta otorrinolaringologica espanola.

[17]  O. Kallioniemi,et al.  Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses , 2006, Oncogene.

[18]  A. Manoharan.  Fanconi anaemia , 2006, British journal of haematology.

[19]  Philippe Thuillier,et al.  Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer. , 2006, Cancer research.

[20]  S. Rogers,et al.  Promoter methylation of P16, RARβ, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing , 2006, British Journal of Cancer.

[21]  J. Surrallés,et al.  Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. , 2006, Cancer letters.

[22]  G. Pals,et al.  Fanconi anemia: adult head and neck cancer and hematopoietic mosaicism. , 2005, Archives of otolaryngology--head & neck surgery.

[23]  P. Rosenberg,et al.  Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. , 2005, Blood.

[24]  J. Herman,et al.  Methylation-Specific PCR Unraveled , 2004, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[25]  T. Crook,et al.  Transcriptional silencing of Fanconi anaemia genes and clinical outcome in head and neck cancer. , 2004, Journal of Clinical Oncology.

[26]  M. Tischkowitz,et al.  Fanconi anaemia and leukaemia – clinical and molecular aspects , 2004, British journal of haematology.

[27]  Katia Basso,et al.  Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. , 2004, Cancer research.

[28]  A. D’Andrea,et al.  Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. , 2004, Blood.

[29]  Mei Liu,et al.  Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival , 2004, Oncogene.

[30]  A. D’Andrea.  The Fanconi road to cancer. , 2003, Genes & development.

[31]  K A Baggerly,et al.  Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. , 2003, BioTechniques.

[32]  N. Tsuchida,et al.  Promoter hypermethylation profile of tumor‐associated genes p16, p15, hMLH1, MGMT and E‐cadherin in oral squamous cell carcinoma , 2003, International journal of cancer.

[33]  J. Shah,et al.  High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. , 2003, Archives of otolaryngology--head & neck surgery.

[34]  F. Arwert,et al.  Breast cancer and Fanconi anemia: what are the connections? , 2002, Trends in molecular medicine.

[35]  M. Esteller.  CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future , 2002, Oncogene.

[36]  K. Kelsey,et al.  Patterns of gene promoter methylation in squamous cell cancer of the head and neck , 2002, Oncogene.

[37]  W. Golusiński,et al.  Analysis of chromosome aberrations in cell lines derived from laryngeal cancer in relation to tumor progression , 2002, European Archives of Oto-Rhino-Laryngology.

[38]  D. Goldenberg,et al.  Epstein-Barr virus and cancers of the head and neck. , 2001, American journal of otolaryngology.

[39]  H. Joenje,et al.  Connecting Fanconi anemia to BRCA1 , 2001, Nature Medicine.

[40]  J. Jen,et al.  Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. , 2001, Cancer research.

[41]  A. Berns,et al.  Mice with a targeted disruption of the Fanconi anemia homolog Fanca. , 2000, Human molecular genetics.

[42]  B. Alter.  Fanconi's anemia and malignancies , 1996, American journal of hematology.

[43]  A. Neder,et al.  Head and neck carcinoma in Fanconi's anaemia--report of a case and review of the literature. , 1995, European journal of cancer. Part B, Oral oncology.